bio for Amy S. Broidrick

Amy S. Broidrick

President and Chief Strategy Officer, Director

Ms. Broidrick has over 27 years’ experience in the biopharmaceutical industry in a variety of functions. Ms. Broidrick was appointed as an independent Director to the Qualigen Therapeutics Board in August 2020, and in December 2020, joined the company as Executive Vice President, Chief Strategy Officer. In December 2021, Ms. Broidrick was promoted to President, Chief Strategy Officer. From 2016 to 2020, she served as Senior Vice President, Global Head of Corporate Development of Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, where she was responsible for building and implementing U.S. and global corporate and business development functions. Before that, she was Vice President, Head of Global Marketing Excellence and Business Innovation with EMD Serono (part of Merck KGaA). Earlier she was Vice President, Head of Marketing and Commercialization at Arena Pharmaceuticals, Inc., and held management roles at Merck & Co., including Global Brand Leader with worldwide P&L accountability, and Pfizer (formerly GD Searle). Ms. Broidrick holds a B.A. from Fairleigh Dickinson University, completed further undergraduate studies at Wroxton College in England, and performed post-graduate work at Fairleigh Dickinson.

Leadership Team

Board of Directors